Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 2/2016

Open Access 01-04-2016

Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors

Authors: Motoki Endo, Yasuo Haruyama, Miyako Takahashi, Chihiro Nishiura, Noriko Kojimahara, Naohito Yamaguchi

Published in: Journal of Cancer Survivorship | Issue 2/2016

Login to get access

Abstract

Purpose

More employees are experiencing a cancer diagnosis during their working-age years, yet there have been no large-scale Japanese studies investigating sick leave due to cancer. We clarified differences in the cumulative partial and full return to work (RTW) rates between different cancer types among Japanese cancer survivors.

Methods

Data on Japanese employees who experienced an episode of sick leave due to clinically certified cancer diagnosed between 1 January 2000 and 31 December 2011 were obtained from an occupational health register. Subject outcomes within the 365-day period following their initial day of sick leave were utilized for this study. We investigated the cumulative partial/full and full RTW rates by using survival analysis with competing risks and predictors of time to RTW by a Fine-Gray proportional hazard regression model.

Results

One thousand two hundred seventy-eight subjects (1033 males and 245 females) experienced their first episode of sick leave due to cancer during the 12-year follow-up period. Of the subjects, 47.1 % returned to work full time within 6 months of their initial day of sick leave absence, and 62.3 % by 12 months. The cumulative RTW rate varied significantly by cancer type. There were considerable differences in the range of cumulative full RTW rates between the two categories (“lower full RTW rate” groups (“lung,” “hepatic, pancreatic,” “esophageal,” and “blood” cancer groups) vs. “higher full RTW rate” groups (“gastric,” “intestinal,” “breast,” “female genital,” “male genital,” “urinary”): 6.3 to 14.3 % vs. 11.4 to 28.3 % at 60 days, 10.6 to 22.4 % vs. 27.0 to 50.0 % at 120 days, 21.3 to 34.7 % vs. 38.5 to 65.4 % at 180 days, 34.3 to 42.9 % vs. 66.0 to 79.5 % at 365 days). Additionally, older age may be associated with a longer time to full RTW.

Conclusions

More than half of the subjects returned to work full-time within the 365-day period following their initial day of sick leave, with cumulative RTW rates varying by cancer type. Older employees may require a longer time to full RTW.

Implications of Cancer Survivors

It is very important for companies (especially small- and medium-sized companies) to establish and improve their RTW support system for cancer survivors, with knowledge that the median time to RTW is expected to be at least a few months.
Literature
1.
Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol/Hematol. 2011;77(2):109–30.CrossRef
2.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96.CrossRefPubMed
3.
Ministry of Health L, Welfare, Japan.: Labor Contract Act. Ministry of Health, Labor, Welfare, Japan 2007.
4.
Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv : Res Pract. 2010;4(4):415–37.CrossRef
5.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A et al.: Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2014.
6.
Verbeek J, Spelten E, Kammeijer M, Sprangers M. Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians. Occup Environ Med. 2003;60(5):352–7.CrossRefPubMedPubMedCentral
7.
Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, et al. The cure of cancer: a European perspective. Eur J Cancer. 2009;45(6):1067–79.CrossRefPubMed
8.
Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007;46(4):417–32.CrossRefPubMed
9.
Marino P, Luis Sagaon T, Laetitia M, le Anne-Gaelle CS. Sex differences in the return-to-work process of cancer survivors 2 years after diagnosis: results from a large French population-based sample. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(10):1277–84.CrossRef
10.
Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014;105(11):1480–6.CrossRefPubMedPubMedCentral
11.
Takahashi M, Kai I, Muto T. Discrepancies between public perceptions and epidemiological facts regarding cancer prognosis and incidence in Japan: an Internet survey. Jpn J Clin Oncol. 2012;42(10):919–26.CrossRefPubMed
12.
Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Japan Cancer Surveillance Research G: Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014;44(4):388–96.CrossRefPubMed
13.
Tamminga SJ, de Boer AG, Verbeek JH, Frings-Dresen MH. Return-to-work interventions integrated into cancer care: a systematic review. Occup Environ Med. 2010;67(9):639–48.CrossRefPubMed
14.
Ministry of Health L, Welfare, Japan.: “Gankanja keikensya no syurousien no arikata ni kansuru kentoukai houkokusyo” (in Japanese). 2014.
15.
Amir Z, Moran T, Walsh L, Iddenden R, Luker K. Return to paid work after cancer: a British experience. J Cancer Surviv : Res Pract. 2007;1(2):129–36.CrossRef
16.
Roelen CA, Koopmans PC, Anema JR, van der Beek AJ. Recurrence of medically certified sickness absence according to diagnosis: a sickness absence register study. J Occup Rehabil. 2010;20(1):113–21.CrossRefPubMedPubMedCentral
17.
Roelen CA, Koopmans PC, Groothoff JW, van der Klink JJ, Bultmann U. Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites. Psycho-Oncology. 2011;20(9):1001–6.PubMed
18.
Gordon LG, Beesley VL, Lynch BM, Mihala G, McGrath C, Graves N, et al. The return to work experiences of middle-aged Australian workers diagnosed with colorectal cancer: a matched cohort study. BMC Public Health. 2014;14:963.CrossRefPubMedPubMedCentral
19.
Spelten ER, Verbeek JH, Uitterhoeve AL, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer. 2003;39(11):1562–7.CrossRefPubMed
20.
Saito N, Takahashi M, Sairenchi T, Muto T. The impact of breast cancer on employment among Japanese women. J Occup Health. 2014;56(1):49–55.CrossRefPubMed
21.
Torp S, Nielsen RA, Gudbergsson SB, Dahl AA. Worksite adjustments and work ability among employed cancer survivors. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer. 2012;20(9):2149–56.CrossRef
22.
Spelten ER, Sprangers MA, Verbeek JH. Factors reported to influence the return to work of cancer survivors: a literature review. Psycho-Oncology. 2002;11(2):124–31.CrossRefPubMed
23.
24.
Cooper AF, Hankins M, Rixon L, Eaton E, Grunfeld EA. Distinct work-related, clinical and psychological factors predict return to work following treatment in four different cancer types. Psycho-Oncology. 2013;22(3):659–67.CrossRefPubMed
25.
Sjovall K, Attner B, Englund M, Lithman T, Noreen D, Gunnars B, et al. Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer. 2012;20(4):741–7.CrossRef
26.
Short PF, Vasey JJ, Tunceli K. Employment pathways in a large cohort of adult cancer survivors. Cancer. 2005;103(6):1292–301.CrossRefPubMed
27.
Carlsen K, Harling H, Pedersen J, Christensen KB, Osler M: The transition between work, sickness absence and pension in a cohort of Danish colorectal cancer survivors. BMJ open 2013, 3(2).
28.
Murray K, Lam KB, McLoughlin DC, Sadhra SS. Predictors of return to work in cancer survivors in the royal air force. J Occup Rehabil. 2015;25(1):153–9.CrossRefPubMed
29.
Hensing G. Swedish Council on Technology Assessment in Health Care (SBU). chapter 4. methodological aspects in sickness-absence research. Scandinav J Public Health Suppl. 2004;63:44–8.CrossRef
30.
Bottcher HM, Steimann M, Rotsch M, Zurborn KH, Koch U, Bergelt C. Occupational stress and its association with early retirement and subjective need for occupational rehabilitation in cancer patients. Psycho-Oncology. 2013;22(8):1807–14.CrossRefPubMed
31.
Roelen CA, Koopmans PC, Schellart AJ, van der Beek AJ. Resuming work after cancer: a prospective study of occupational register data. J Occup Rehabil. 2011;21(3):431–40.CrossRefPubMedPubMedCentral
32.
Sampere M, Gimeno D, Serra C, Plana M, Martinez JM, Delclos GL, et al. Organizational return to work support and sick leave duration: a cohort of Spanish workers with a long-term non-work-related sick leave episode. J Occupation Environm Med / Am College Occupation Environ Med. 2011;53(6):674–9.CrossRef
33.
Horsboel TA, Nielsen CV, Andersen NT, Nielsen B, de Thurah A. Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study. Acta Oncol. 2014;53(6):724–34.CrossRefPubMed
34.
The clinical guideline of haematological malignancies 2013 (in Japanese).
35.
Harrison’s principal of internal medicine 15th edition volume 1.
36.
Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751–8.CrossRefPubMed
37.
Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol : Off J Div Health Psychol, Am Psychol Assoc. 2010;29(2):160–8.CrossRef
38.
Nissim R, Gagliese L, Rodin G. The desire for hastened death in individuals with advanced cancer: a longitudinal qualitative study. Soc Sci Med. 2009;69(2):165–71.CrossRefPubMed
39.
van Muijen P, Duijts SF, van der Beek AJ, Anema JR. Prognostic factors of work disability in sick-listed cancer survivors. J Cancer Survivor : Res Pract. 2013;7(4):582–91.CrossRef
40.
Mehnert A, Koch U. Predictors of employment among cancer survivors after medical rehabilitation--a prospective study. Scandinav J Work, Environ Health. 2013;39(1):76–87.CrossRef
41.
van Muijen P, Weevers NL, Snels IA, Duijts SF, Bruinvels DJ, Schellart AJ, et al. Predictors of return to work and employment in cancer survivors: a systematic review. Europ J Cancer Care. 2013;22(2):144–60.CrossRef
42.
Taskila T, Lindbohm ML. Factors affecting cancer survivors’ employment and work ability. Acta Oncol. 2007;46(4):446–51.CrossRefPubMed
43.
Ministry of Health L, Welfare, Japan.: The patient survey 2008 (in Japanese). 2008.
44.
Christensen KB, Andersen PK, Smith-Hansen L, Nielsen ML, Kristensen TS. Analyzing sickness absence with statistical models for survival data. Scandinav J Work, Environ Health. 2007;33(3):233–9.CrossRef
45.
Nilsson M, Olsson M, Wennman-Larsen A, Petersson LM, Alexanderson K. Return to work after breast cancer: women’s experiences of encounters with different stakeholders. Europ J Oncol Nurs : Off J Europ Oncol Nursing Soc. 2011;15(3):267–74.CrossRef
46.
Satariano WA, DeLorenze GN. The likelihood of returning to work after breast cancer. Public Health Rep. 1996;111(3):236–41.PubMedPubMedCentral
47.
Ohguri T, Narai R, Funahashi A, Nishiura C, Yamashita T, Yarita K, et al. Limitations on work and attendance rates after employees with cancer returned to work at a single manufacturing company in Japan. J Occup Health. 2009;51(3):267–72.CrossRefPubMed
Metadata
Title
Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors
Authors
Motoki Endo
Yasuo Haruyama
Miyako Takahashi
Chihiro Nishiura
Noriko Kojimahara
Naohito Yamaguchi
Publication date
01-04-2016
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2016
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0478-3

Other articles of this Issue 2/2016

Journal of Cancer Survivorship 2/2016 Go to the issue

OriginalPaper

Factors associated with childhood cancer survivors’ knowledge about their diagnosis, treatment, and risk for late effects

OriginalPaper

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study

OriginalPaper

Gender differences in cost-related medication non-adherence among cancer survivors

OriginalPaper

Survivors of gynecologic malignancies: impact of treatment on health and well-being

OriginalPaper

Quality of working life of cancer survivors: development of a cancer-specific questionnaire

OriginalPaper

Social networks and social support for healthy eating among Latina breast cancer survivors: implications for social and behavioral interventions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits